Laser therapy and unloading therapeutic gymnastics in the treatment of dyslipoproteinemia-Reference-Cited by-同舟云学术

Laser therapy and unloading therapeutic gymnastics in the treatment of dyslipoproteinemia

Published:2024-03 Issue:2024(1) Volume: Page:
ISSN:
Container-title:Medicine of Extreme Situations
language:ru
Short-container-title:MES

Author:

Achilov AA¹,Baranov AV¹,Gornov SV²,Usmonzoda DU³,Achilova SA⁴,Pulatova MD⁵,Achilov AlA⁶,Mamedyarova IA⁷,Lazechko MI¹

Affiliation:

1. The Skobelkin Research and Practical Centre for Laser Medicine of the Federal Medical-Biological Agency, Moscow, Russia

2. Russian Biotechnological University, Institute of Medical Continuous Education, Moscow, Russia

3. Diagnostic Clinical Center № 1 of the Moscow City Health Department, Branch 3. Moscow, Russia

4. SCOLMED LLC, Zarechye, Moscow, Russia

5. Municipal Polyclinic № 134 of the Moscow City Health Department, Moscow, Russia

6. Vishnevsky Central Military Clinical Hospital of the Russian Federation Defence, Moscow, Russia

7. Azerbaijan Medical University, Baku, Azerbaijan

Abstract

Based on clinical practice, some patients with lipid metabolism disorders (LMD) are resistant to lipid-lowering therapy (LLT) — in such patients, taking optimal doses of LLT drugs does not reduce levels of cholesterol and its fractions to target levels and using LLT at higher doses is associated with increased odds of adverse events. To optimize the treatment, 58 patients with ischemic heart disease with LMD resistant to LLT were examined. The patients were divided into two groups: in the main group, 29 patients received laser therapy and unloading therapeutic gymnastics; in the control group, 29 patients continued to take their usual medications. The obtained results showed a significant lipid-lowering effect of the treatment in the main group: we observed a significant decrease in total cholesterol (by 27.7%, p < 0.01) as well as low-density lipoprotein cholesterol (by 34.7%, p < 0.01), a significant increase in high-density lipoprotein cholesterol (28.1%, p < 0.01), a significant decrease of atherogenic coefficient (by 50.2%, p < 0.01) and in the levels of triglycerides (by 49.6%, p < 0.01). At the same time, no significant positive changes in lipid profile were observed in the control group. In patients of the main group, tolerance to physical activity increased significantly, with statistically insignificant changes in the control group accordingly.

Publisher

Federal Medical Biological Agency

Reference33 articles.

1. Achilov AA, inventor. Method for preventing, treating and regressing hypertonic disease, atherosclerosis, ischemic cardiac disease, circulatory insufficiency. Russian Federation patent № 2245700. 10.02.2005. Russian.

2. Achilov AA, Baranov AV, Achilova ShA, Lebedeva OD, Kornev OD, Airapetova TL. Optimization of complex treatment of patients with severe arterial hypertension. Clin Gerontol. 2021; 27 (1–2): 76–83. Russian.

3. Achilov AA, inventor. Method for preventing, treating and regressing hypertonic disease, atherosclerosis, ischemic cardiac disease, circulatory insufficiency. Evraziyskiy patent № 004621 от 24.06.2004. Russian.

4. Karpov YuA. How to enhance control of low-density lipoprotein cholesterol in reducing cardiovascular risk? Atmosfera. Novosti kardiologii. 2021; 1: 3–12. Russian.

5. Karpov YuA. Efficacy and safety of achieving novel low-density lipoprotein cholesterol target levels: the role of combination therapy. Atmosfera. Novosti kardiologii. 2021; 2: 3–11. Russian.